Overview
- Editors:
-
-
Robert K. Hamatake
-
Ribapharm Inc., Costa Mesa
-
Johnson Y. N. Lau
-
Ribapharm Inc., Costa Mesa
Access this book
Other ways to access
Table of contents (36 protocols)
-
Front Matter
Pages i-xxiii
-
Viral-Specific Immunological and Other Host Responses
-
-
- Darren S. Miller, Edward M. Bertram, Catherine A. Scougall, Ieva Kotlarski, Allison R. Jilbert
Pages 3-25
-
- Stephan Menne, Paul J. Cote
Pages 27-36
-
- Mengji Lu, Michael Roggendorf
Pages 37-42
-
- Michael Geissler, Robert Weth, Christian F. Grimm, Dörte Ortmann, Hubert E. Blum
Pages 43-54
-
- Michael R. Beard, Stephen Locarnini
Pages 55-64
-
- Michelina Nascimbeni, Barbara Rehermann
Pages 65-83
-
- Jennifer A. Waters, Howard C. Thomas
Pages 85-88
-
- Xiao-Song He, Harry B. Greenberg
Pages 89-96
-
- Shilpa Chokshi, Nikolai V. Naoumov
Pages 97-109
-
- Ren-Shiang Lee, Shih-Jer Hsu, Li-Rung Huang, Hui-Lin Wu, Shiou-Lin Lin, Ding-Shinn Chen et al.
Pages 111-128
-
In Vitro and In Vivo Models
-
Front Matter
Pages 129-129
-
- Azeneth Barrera, Robert E. Lanford
Pages 131-142
-
- Dieter Glebe, Wolfram H. Gerlich
Pages 143-152
-
- Fritz von Weizsäcker, Josef Köck, Sabine MacNelly, Shaotang Ren, Hubert E. Blum, Michael Nassal
Pages 153-161
-
- Masayoshi Konishi, Catherine H. Wu, George Y. Wu
Pages 163-173
-
- Norma D. Churchill, Tomasz I. Michalak
Pages 175-187
-
- Olivier Hantz, Fabien Zoulim
Pages 189-197
-
- Xuanyong Lu, Timothy M. Block
Pages 199-208
About this book
Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with HCC arises because the disease is often detected late and is unresponsive to treatment. The number of deaths caused by PHCC is expected to rise over the next 20 years. Those chronically infected with HBV have a life risk of death to HCC of between 10 and 25%. Even the limited efficacy of drugs for the treatment of chronic HBV helps underscore the point that this disease is responsive to therapy. Drugs that target the polymerase (e. g. , hepsera and lamivudine) and interferon alpha represent two distinct strategies and show that both conventional antiviral and immunothe- peutic approaches can be used in management. However, the current inventory of therapeutics is inadequate. Interferon alpha is of limited value, only parenterally ava- able, and fraught with adverse reactions.
Reviews
"Both volumes provide an excellent reference for background information and detailed experimental investigations for both Hepatitis B and Hepatitis D. A major attribute of the volumes is that as they cover a wide range of subjects, the reader has the opportunity to access information they would not normally encounter. Volumes 1 and 2 are an excellent reference source and the methodologies described present the opportunity for both new and experienced researchers to study the molecular aspects of HBV and HDV infection."-SGM Quarterly
"...an excellent reference for background information and detailed experimental investigations for both Hepatitis B and Hepatitis D..." - Microbiology Today
